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Murakawa and associates report a succinct and well-
designed sequence of experiments that suggest that
carefully controlled cryopreservation does not reduce
the immunogenicity of human fibroblasts. They chose
lung fibroblasts in tissue culture as a model of allograft
fibroblasts and found that their spontaneous prolifera-
tion, marginal ability to stimulate allogeneic lympho-
cytes, and basal expression of class I human leukocyte
antigens (HLA) and intracellular adhesion molecule-1
(ICAM-1) were all unaffected by cryopreservation.
Furthermore, the up-regulation of these molecules and
the induction of class II HLA on the fibroblast mem-
brane by interferon-gamma (INF-γ) occurred to the
same level in both freshly cultured and cryopreserved
cells.
By implication, aortic valve fibroblasts that survive
cryopreservation may play some part in the immune
response mounted against the allograft by the recipi-
ent. However, fibroblasts, even after exposure to INF-
γ, cannot initiate an anti-graft response as they lack
the antigen-presenting capacity and particular co-
stimulatory molecules that only dendritic cells pos-
sess. The authors’ data suggest that INF-γ–primed
fibroblasts could amplify the ongoing immune
response by prolonging the activation of recipient T
cells infiltrating the allograft. It must also be noted
that the expression of class I and II HLA and ICAM-
1 by activated fibroblasts exposes them to cytolysis by
T cells with likely detrimental effects on allograft
structure and function.
There is now evidence that fibroblasts, as well as
endothelial cells, may play their part in the immuno-
logic damage that aortic valve allografts are likely to
sustain after implantation. However, as lung fibroblasts
may differ in their phenotype from those in vascular
tissue, the authors should be encouraged to extend their
studies to human aortic valve fibroblasts. In the mean-
time, several groups continue to probe the interstitium
of aortic valves looking for dendritic cells with potent
alloantigen-presenting capacity.
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